Amy Hankin

Also affiliated with National Cancer Institute

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 17 papers. Top paper: “Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response”.

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2344

N/A

1.2DataRank · unranked

38 citations

Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih, Maria J. Merino +20 more

PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.105

N/A

0.312DataRank · unranked

7 citations

Fatima Karzai, Jennifer L. Marté, Marijo Bilušić, Sheri McMahon, Julius Strauss +10 more

Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.093

N/A

0.241DataRank · unranked

4 citations

Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +15 more

Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17033

N/A

0.208DataRank · unranked

3 citations

Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +15 more

Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e17044

N/A

0.104DataRank · unranked

1 citations

Shruti U. Gandhy, Fatima Karzai, Marijo Bilušić, Lisa M. Cordes, Helen Owens +8 more

Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e17569

N/A

0.104DataRank · unranked

1 citations

Fatima Karzai, Jennifer L. Marté, Marijo Bilušić, Sheri McMahon, Julius Strauss +13 more

First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report

Frontiers in Oncology(2023)10.3389/fonc.2023.1126476

N/A

0.104DataRank · unranked

1 citations

Danielle M. Pastor, Fatima Karzai, Amy Hankin, Barış Türkbey, Lisa M. Cordes +5 more

PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17046

N/A

0.104DataRank · unranked

1 citations

Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilušić +15 more

Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer

British Journal of Urology(2020)10.1111/bju.15227

N/A

0DataRank · unranked

13 citations

Fatima Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen +22 more

Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.180

N/A

0DataRank · unranked

0 citations

Fatima Karzai, Philip M. Arlen, Clara Chen, Esther Mena, Liza Lindenberg +11 more

Anaplastic features (AnaF) and DNA-damage repair pathway (DDR) mutations in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.92

N/A

0DataRank · unranked

0 citations

Ravi A. Madan, Marijo Bilušić, Lisa M. Cordes, Jennifer L. Marté, Helen Owens +6 more

Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.130

N/A

0DataRank · unranked

3 citations

Mohammad Atiq, Renee N. Donahue, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +11 more

Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.207

N/A

0DataRank · unranked

0 citations

Meghali Goswami, Renee N. Donahue, Mohammad Atiq, Fatima Karzai, Marijo Bilušić +13 more

Data from Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

(2023)10.1158/1078-0432.c.6530054

N/A

0DataRank · unranked

0 citations

Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih, Maria J. Merino +20 more

Data from Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

(2023)10.1158/1078-0432.c.6530054.v1

N/A

0DataRank · unranked

0 citations

Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih, Maria J. Merino +20 more

A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5101

N/A

0DataRank · unranked

0 citations

Liza Lindenberg, Esther Mena Gonzalez, Barış Türkbey, Fatima Karzai, Megan Hausler +8 more

1631P Results from the quick efficacy seeking trial (QuEST1) arm combining BN-brachyury (BNVax) + bintrafusp alfa (BA) + nogapendekin alfa inbakicept-pmln (N-803) in castration-resistant prostate cancer (CRPC)

Annals of Oncology(2024)10.1016/j.annonc.2024.08.1712

N/A

0DataRank · unranked

3 citations

Ravi A. Madan, Fatima Karzai, Lisa M. Cordes, Jenn Marte, N. Williams +9 more